Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab

Novel therapeutic approaches combining immune-checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune-checkpoint molecule that inhibits T-cell activity and antitumor immune responses, acting through an independent mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Thudium, Kent, Selby, Mark, Zorn, Julie A., Rak, Gregory, Wang, Xi-Tao, Bunch, Roderick Todd, Hogan, Jason M., Strop, Pavel, Korman, Alan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530649/
https://www.ncbi.nlm.nih.gov/pubmed/35981087
http://dx.doi.org/10.1158/2326-6066.CIR-22-0057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530649/
https://www.ncbi.nlm.nih.gov/pubmed/35981087
http://dx.doi.org/10.1158/2326-6066.CIR-22-0057

Ejemplares similares